# Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection

> **NCT02527460** · PHASE1 · TERMINATED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 1 (actual)

## Conditions studied

- HIV Infections
- Neurologic Disorders

## Interventions

- **DRUG:** Anakinra

## Key facts

- **NCT ID:** NCT02527460
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-17
- **Primary completion:** 2018-03-02
- **Final completion:** 2018-03-02
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2019-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02527460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02527460, "Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02527460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*